EDWARDS LIFESCIENCES CORPORATION
In the published model solve dated 2026-Q2, anchored at $90.21, EDWARDS LIFESCIENCES CORPORATION (EW) is priced for today's economics sustained for ~5.8 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Three quarters of revenue comes from one procedure, threading a replacement aortic valve up an artery instead of opening the chest, with the newer mitral and tricuspid line at ⟦"9%, 7%, and 4% of our net sales in 2025, 2024, and 2023, respectively"⟧ and surgical tissue valves at 17% of 2025 sales. • Reported operating profit went backwards in 2025 even as sales rose $628.1 million, because intellectual property litigation expenses, settlements, and external legal costs jumped to $325.4 million
Is EW overvalued? See what's priced in →
1,255 institutional managers reported holding EW in 13F filings for the quarter ended 2026-03-31. Together they hold about 71% of the company; the top 10 hold 33%. 93 opened new positions that quarter. Held by BlackRock, State Street, Wellington Management, among others. On the short side, 11.8M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
EW has cut its share count 6.9% over the past five years, spending $5.30B on repurchases. It pays no dividend. Cash returned over the past three years: $3.21B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at EW over the trailing three years: 2024: 1 buy totaling $50k. 19 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
EW's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-29 | -9.8% | -17.3% |
| 2023-10-28 | -10.9% | +23.6% |
| 2024-02-13 | +0.6% | +4.4% |
| 2024-04-30 | -2.5% | +7.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
EW's latest 8-K filings: 2026-08-28 (items 5.02); 2026-07-23 (items 2.02, 9.01); 2026-05-08 (items 5.02, 5.07, 9.01); 2026-05-04 (items 5.02, 7.01); 2026-04-23 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.